Method of Treating Kcnq Related Disorders Using Organozinc Compounds
AssigneeThe Johns Hopkins University
InventorsMin Li, Haiyan Sun, Qiaojie Xiong
Life of this patent
Estimating the term…
Abstract
The instant invention describes methods of treating KCNQ related diseases and disorders using organozinc compounds. In certain embodiments, pain is treated using Zinc Pyrithione.
Claims60
A method of treating a KCNQ related disorder in a subject, comprising administering to said subject, an effective amount of a KCNQ polypeptide channel activity modulator, such that said subject is treated for said disorder;
- wherein the KCNQ polypeptide channel activity modulator is an organozinc compound.
A method of treating a KCNQ related disorder in a subject, wherein the subject has been identified as in need of treatment for a KCNQ related disorder, comprising administering to said subject in need thereof, an effective amount of a KCNQ polypeptide channel activity modulator, such that said subject is treated for said disorder;
- wherein the modulator of a KCNQ polypeptide channel is an organozinc compound.
A method of protecting against the effects of pain comprising, administering to a subject in need thereof, a pharmaceutically effective amount of a KCNQ polypeptide channel activity modulator;
- wherein the modulator is an organozinc compound.
A method of modulating the activity of a potassium channel in a subject, comprising contacting a potassium channel with an organozinc compound.
A method for identifying a compound which modulates the activity of a KCNQ polypeptide channel, the method comprising:
- a) contacting a KCNQ polypeptide channel with a compound under conditions suitable for modulation of the activity of the KCNQ polypeptide channel;
- and
- b) detecting modulation of the activity of the KCNQ polypeptide channel by the compound;
- wherein the compound chemically interacts with the KCNQ polypeptide channel.
A method of treating a KCNQ mutation disorder in a subject, comprising administering to the subject, an effective amount of a KCNQ polypeptide channel activity potentiator, such that said subject is treated for said disorder,
- wherein the potentiator is an organozinc compound.
A method of treating a KCNQ mutation disorder in a subject, wherein the subject has been identified as in need of treatment for a KCNQ mutation disorder, comprising administering to said subject in need thereof, an effective amount of a KCNQ polypeptide channel activity potentiator, such that said subject is treated for said disorder;
- wherein the potentiator is an organozinc compound.
Dependencies are inferred from the claim text.